|
3 Companies |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
0 Trials |
|
11 News |
|
- Givlaari (givosiran) / Alnylam
Trial primary completion date: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) (clinicaltrials.gov) - Nov 27, 2017
P1, N=40, Completed, Sponsor: Alnylam Pharmaceuticals
Trial primary completion date: May 2017 --> Sep 2017
- | Givlaari (givosiran) / Alnylam
Trial completion, Enrollment change: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) (clinicaltrials.gov) - Sep 8, 2017
P1, N=40, Completed, Sponsor: Alnylam Pharmaceuticals
Trial primary completion date: May 2017 --> Sep 2017 Recruiting --> Completed | N=72 --> 40
- || Givlaari (givosiran) / Alnylam
Enrollment change: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) (clinicaltrials.gov) - Jun 5, 2017
P1, N=72, Recruiting, Sponsor: Alnylam Pharmaceuticals
Recruiting --> Completed | N=72 --> 40 N=48 --> 72
- | chlorpromazine / Generic mfg.
Trial completion: Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride (clinicaltrials.gov) - Dec 14, 2016
P1, N=20, Completed, Sponsor: Cycle Pharmaceuticals Ltd.
N=48 --> 72 Active, not recruiting --> Completed
- chlorpromazine / Generic mfg.
Enrollment closed: Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride (clinicaltrials.gov) - Nov 22, 2016
P1, N=20, Active, not recruiting, Sponsor: Cycle Pharmaceuticals Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- Givlaari (givosiran) / Alnylam
Trial primary completion date: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) (clinicaltrials.gov) - Oct 31, 2016
P1, N=48, Recruiting, Sponsor: Alnylam Pharmaceuticals
Not yet recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Feb 2017
- | chlorpromazine / Generic mfg.
New P1 trial: Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride (clinicaltrials.gov) - Oct 25, 2016
P1, N=20, Not yet recruiting, Sponsor: Cycle Pharmaceuticals Ltd.
- | Givlaari (givosiran) / Alnylam
New P1 trial: A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP) (clinicaltrials.gov) - May 22, 2015
P1, N=48, Recruiting, Sponsor: Alnylam Pharmaceuticals
- Trial completion, Gene therapy: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria (clinicaltrials.gov) - Dec 19, 2014
P1, N=8, Completed, Sponsor: Digna Biotech S.L.
Trial primary completion date: Jun 2016 --> Feb 2017 Active, not recruiting --> Completed
- New P1 trial, Gene therapy: Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria (clinicaltrials.gov) - Mar 6, 2014
P1, N=8, Active, not recruiting, Sponsor: Digna Biotech S.L.
- Clinical: Observational Study of Acute Intermittent Porphyria Patients (clinicaltrials.gov) - Mar 2, 2014
P=N/A, N=9, Completed, Sponsor: Digna Biotech S.L.